A PYMNTS Company

US: Pfizer wants Washington support for $160bn Allergan deal

By  |  November 23, 2015

Pfizer’s chief executive has called on Washington to support its $160bn takeover of Dublin-based Allergan the Financial Times reported. This is in response to politicians including Hillary Clinton that are lined up against the drugmaker’s attempt to slash its tax bill by moving overseas.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The third-largest announced deal in history caps a frenzied year of mergers and acquisitions, bringing the total value of global transactions announced since the start of 2015 to more than $4.2tn. This surpasses the previous record set in 2007 on the eve of the financial crisis, according to Thomson Reuters.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    “I cannot comprehend why it’s not being applauded by the political class, or why anyone would want to frustrate this transaction,” Mr Read told the Financial Times. “It’s a great deal for the US, given that it frees up our ability to invest in American science.”

    In an attempt to circumvent any political attempt to torpedo the deal, the transaction will be structured as a reverse merger, with Allergan technically buying Pfizer. Allergan will be renamed Pfizer and the new company will continue to trade on the New York Stock Exchange under the PFE ticker.

    Full content: The Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.